Something to Smile about

SRxA‘s Word on Health broke out a wrinkle-free smile at the news that Allergan’s Botox sales have increased 5.6% over the last quarter.  Sales of the popular cosmetic injections have been declining during the past few quarters mainly due to weak consumer spending and increased competition.

Going forward,  Allergan is looking to grow Botox sales further by gaining approval for additional indications. The company has recently filed for FDA approval of Botox for the treatment of chronic migraine.

SRxA‘s Word on Health hopes this news not only relieves headaches but also  heralds an  upturn in the economy.